Amine Linked Flavonoid Dimers as Modulators for P-Glycoprotein-Based Multidrug Resistance: Structure-Activity Relationship and Mechanism of Modulation

被引:69
作者
Chan, Kin-Fai [1 ,2 ]
Wong, Iris L. K. [1 ,2 ]
Kan, Jason W. Y. [1 ,2 ]
Yan, Clare S. W. [1 ,2 ]
Chow, Larry M. C. [1 ,2 ]
Chan, Tak Hang [1 ,2 ,3 ]
机构
[1] Hong Kong Polytech Univ, State Key Lab Chirosci, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China
[2] Hong Kong Polytech Univ, State Key Lab Chinese Med & Mol Pharmacol, Shenzhen, Peoples R China
[3] McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada
关键词
HUMAN BREAST-CANCER; CYCLOSPORINE-A; BIVALENT MODULATORS; CELL-LINE; IN-VITRO; DAUNORUBICIN RESISTANCE; VINCRISTINE RESISTANCE; CALMODULIN INHIBITORS; APIGENIN HOMODIMERS; CALCIUM-ANTAGONISTS;
D O I
10.1021/jm201121b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Here we report a great improvement in reversal potency of cancer drug resistance when flavonoid dimers possess a functionally substituted aminopolyethylene glycol linker. The most potent compound, 18, contains a N-benzyl group at the linker. It has many advantages including (1) high potencies in reversing P-glycoprotein (P-gp) mediated resistance in LCC6MDR cells to various anticancer drugs with EC50 in the nanomolar range, (2) low toxicity and high therapeutic index, and (3) preferential inhibition of P-gp over multidrug resistance protein 1 and breast cancer resistance protein. Compound 18 stimulates P-gp-ATPase activity by 2.7-fold and mediates a dose-dependent inhibition of doxorubicin (DOX) transport activity. Lineweaver-Burk and Dixon plots suggest that 18 is a competitive inhibitor to DOX in binding to P-gp with a K-i of 0.28-0.34 mu M and a Hill coefficient of 1.17. Moreover, the LCC6MDR cell displays about 2.1-fold lower intracellular accumulation of 18 compared to the wild type, suggesting that 18 is a P-gp substrate as well.
引用
收藏
页码:1999 / 2014
页数:16
相关论文
共 51 条
[11]   EFFECTS OF FLAVONOLS ON P-GLYCOPROTEIN ACTIVITY IN CULTURED RAT HEPATOCYTES [J].
CHIELI, E ;
ROMITI, N ;
CERVELLI, F ;
TONGIANI, R .
LIFE SCIENCES, 1995, 57 (19) :1741-1751
[12]   C-isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance [J].
Comte, G ;
Daskiewicz, JB ;
Bayet, C ;
Conseil, G ;
Viornery-Vanier, A ;
Dumontet, C ;
Di Pietro, A ;
Barron, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (05) :763-768
[13]   MODULATION OF ADRIAMYCIN(R) ACCUMULATION AND EFFLUX BY FLAVONOIDS IN HCT-15 COLON CELLS - ACTIVATION OF P-GLYCOPROTEIN AS A PUTATIVE MECHANISM [J].
CRITCHFIELD, JW ;
WELSH, CJ ;
PHANG, JM ;
YEH, GC .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (07) :1437-1445
[14]   CORRELATION BETWEEN POTENCY OF CALMODULIN INHIBITORS AND EFFECTS ON CELLULAR-LEVELS AND CYTO-TOXIC ACTIVITY OF DOXORUBICIN (ADRIAMYCIN) IN RESISTANT P388 MOUSE LEUKEMIA-CELLS [J].
GANAPATHI, R ;
GRABOWSKI, D ;
TURINIC, R ;
VALENZUELA, R .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (06) :799-806
[15]   Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro [J].
Germann, UA ;
Shlyakhter, D ;
Mason, VS ;
Zelle, RE ;
Duffy, JP ;
Galullo, V ;
Armistead, DM ;
Saunders, JO ;
Boger, J ;
Harding, MW .
ANTI-CANCER DRUGS, 1997, 8 (02) :125-140
[16]   P-glycoprotein - A mediator of multidrug resistance in tumour cells [J].
Germann, UA .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (06) :927-944
[17]   Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP [J].
Germann, UA ;
Ford, PJ ;
Shlyakhter, D ;
Mason, VS ;
Harding, MW .
ANTI-CANCER DRUGS, 1997, 8 (02) :141-155
[18]  
GRUOL DJ, 1994, CANCER RES, V54, P3088
[19]  
Harborne J B, 1986, Prog Clin Biol Res, V213, P15
[20]   REVERSAL OF MULTIDRUG RESISTANCE BY B859-35, A METABOLITE OF B859-35, NIGULDIPINE, VERAPAMIL AND NITRENDIPINE [J].
HOFMANN, J ;
WOLF, A ;
SPITALER, M ;
BOCK, G ;
DRACH, J ;
LUDESCHER, C ;
GRUNICKE, H .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 118 (05) :361-366